53 results
Plenary 3 begins at 20:00. Ashley Birkett, PATH; Mark Hatherill, SATVI; Shan Lu, China NMCID; Punnee Pitisuttithum, Mahidol U; Lynda Stuart, BioNTech
Each year, WHO’s World malaria report offers in-depth information on the latest trends in malaria control and elimination at global, regional and country levels. The report highlights progress...
Le programme de mise en œuvre de la vaccination antipaludique en Afrique
Depuis 2019, le vaccin est administré dans 3 pays par le biais de programmes nationaux de vaccination des enfants dans le...
The RTS,S/AS01 malaria vaccine. Significantly reduces malaria and life-threatening severe malaria. Since 2019, delivered in childhood vaccination in 3 country-led pilots.
GVIRF 2023 Presentation
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO publishes vaccine position papers providing global vaccine and immunization recommendations for...
The WHO website provides a list of certain diseases for which vaccines are available, and a list of some pathogens for which vaccines and/or monoclonal antibodies (mAbs) are in development. For each...
Conformément à son mandat, qui prévoit qu’elle conseille les États Membres en matière de politique sanitaire, l’OMS publie une série de notes de synthèse régulièrement mises à jour sur...
This market study was initiated in order to help establish a common understanding of the malaria vaccine market in the near and long term (2022-2036) and to support timely access
to the vaccine...
Role of CHMI in malaria vaccine development, rationale for human infection studies in semi-immune adults in Kenya, work in progress and future developments
Q&A on the Phase 3 trial results for malaria vaccine RTS,S/AS01
Q&A on the malaria vaccine implementation programme (MVIP)
A first generation vaccine known as RTS,S/AS01 (RTS,S) acts against Plasmodium falciparum, the most deadly malaria parasite globally and the most prevalent in Africa. The vaccine provides partial...
The World Malaria Report 2017 draws on data from 91 countries and areas with ongoing malaria transmission. The information is supplemented by data from national household surveys and databases held...
Background: Plasmodium falciparum sporozite (PfSPZ) Vaccine is a metabolically active, non-replicating, whole malaria sporozoite vaccine that has been reported to be safe and protective against P...
Background
Despite remarkable progress in the improvement of child survival between 1990 and 2015, the Millennium Development Goal (MDG) 4 target of a two-thirds reduction of under-5 mortality rate...
The World Malaria Report 2016 summarizes information received from malaria-endemic countries and other sources, and updates the analyses presented in the 2015 report.
The World Malaria Report is...
Background
RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in endemic Africa. Model predictions of impact and cost-effectiveness of this new intervention...
Malaria remains a major global public health concern, especially in sub-Saharan Africa. The RTS,S/AS01 malaria candidate vaccine was reviewed by the European Medicines Agency and received a positive...
RTS,S/AS01 is a malaria vaccine candidate that has undergone phase 3 evaluation across several sites in Africa that have varying intensities of malaria transmission. During more than 48 months of...
Health facility stock-outs of life saving malaria medicines are common across Africa. Innovative ways of addressing this problem are urgently required. We evaluated whether SMS based reporting of...
Since the 1915 launch of the first international eradication initiative targeting a human pathogen, much has been learned about the determinants of eradicability of an organism. The authors outline...
Guidelines for Managing the Malaria Supply Chain: A Companion to the Logistics Handbook is a practical guidebook on supply chain management with an emphasis on antimalarial health products. The text...
In May 2015, the World Health Assembly endorsed a new Global Technical Strategy for Malaria. The strategy includes ambitious goals for malaria control and elimination in the next 15-year period. A...
This is the first WHO position paper on a malaria vaccine. It focuses primarily on the available evidence concerning the only candidate malaria vaccine to have received a positive regulatory...
The phase 3 trial of the RTS,S/AS01 malaria vaccine candidate showed modest efficacy of the vaccine against Plasmodium falciparum malaria, but was not powered to assess mortality endpoints. Impact...
The diversity of parental positions regarding vaccinating their infants against malaria implies that malaria vaccination campaigns in Togo, and possibly in other sub-Saharan African countries, must...
Malaria vaccine research has been intensified over the past few years with several vaccines tested in trials. RTS,S vaccine has been the most promising of these candidates. The vaccine consists of P...
A primary concern for the RTS,S malaria vaccine candidate is duration of protection. The ongoing Phase III trial reported evidence of waning efficacy within the first year following vaccination....
P. falciparum is highly virulent in nature because of its the ability to modify the infected host red blood cells, adherence to the vascular endothelium and changes in antigenicity at different...
The deployment of a safe and effective malaria vaccine will be an important tool for the control of malaria and the reduction in malaria deaths. With the launch of the 2030 Malaria Vaccine Technology...
Electronic data capture took place in 11 sentinel health centres in rural southern Tanzania. Information from children attending the outpatient department (OPD) and the Expanded Program on...
BACKGROUND: Defining the number and location of sprayable structures (houses) is foundational to plan and monitor indoor residual spray (IRS) implementation, a primary intervention used to control...
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. The researchers...
Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing...
Malaria remains a major health burden especially for the developing countries. Despite concerted efforts at using the current control tools, such as bed nets, anti malarial drugs and vector control...
No licensed vaccines are available for malaria or any other human parasitic disease. The most advanced malaria vaccine candidate is RTS,S/AS01, which is directed against Plasmodium falciparum...
This article analyses the WHO policy development process to predict its course for a malaria vaccine.
The WHO Malaria Advisory Committee (MALVAC) provides advice to WHO on strategic priorities, activities and technical issues related to global efforts to develop vaccines against malaria. MALVAC...
A mathematical modelling tool that estimates the impact of scaling up high-impact MNCH and nutrition interventions in low- and middle-income countries. It estimates the impact of these interventions...